Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Invested Capital (2020 - 2026)

Journey Medical filings provide 6 years of Invested Capital readings, the most recent being $31.9 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 29.14% to $31.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.9 million, a 29.14% decrease, with the full-year FY2025 number at $31.9 million, down 29.14% from a year prior.
  • Invested Capital hit $31.9 million in Q4 2025 for Journey Medical, up from $31.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $56.2 million in Q1 2022 to a low of -$11.7 million in Q3 2021.
  • Median Invested Capital over the past 5 years was $30.9 million (2024), compared with a mean of $28.7 million.
  • Biggest five-year swings in Invested Capital: crashed 271.61% in 2021 and later skyrocketed 6361.99% in 2022.
  • Journey Medical's Invested Capital stood at $42.9 million in 2021, then rose by 4.41% to $44.7 million in 2022, then decreased by 21.85% to $35.0 million in 2023, then grew by 28.53% to $44.9 million in 2024, then decreased by 29.14% to $31.9 million in 2025.
  • The last three reported values for Invested Capital were $31.9 million (Q4 2025), $31.5 million (Q3 2025), and $23.0 million (Q2 2025) per Business Quant data.